Numbers Flashcards
<p>PKU incidence</p>
<p>1:100,000</p>
<p>PKU and risk congenital heart defect</p>
<p>7-10%</p>
<p>Fetal Phe levels </p>
<p>1.25-2.5x more than maternal</p>
<p>Woman >40yo how many pregnancies unplanned?</p>
<p>20%</p>
<p>Percentage of TOP in women >40yo</p>
<p>28%</p>
<p>Background risk VTE in non-pregnant non-contraceptive users</p>
<p>2:10,000</p>
<p>% normal population with anti phospholipid antibodies </p>
<p>1-2%</p>
<p>% of those with recurrent thrombosis with APS</p>
<p>20%</p>
<p>% of those with recurrent miscarriage with APS</p>
<p>15%</p>
<p>Risk of female carrier BRCA 1 developing breast cancer <70</p>
<p>60-80%</p>
<p>Risk of female carrier of BRaC-2 developing breast ca <70</p>
<p>45-85%</p>
<p>Incidence ectopic UK</p>
<p>11:1000</p>
<p>Incidence perforation in OP hysteroscopy</p>
<p>0.002-1.7%</p>
<p>Incidence of perforation in hysteroscopic surgery</p>
<p>1.6%</p>
<p>Perforation in ERPC for PPH</p>
<p>5%</p>
<p>Perforation for PMB Ix</p>
<p>0.2-2%</p>
<p>Perforation in TOP</p>
<p>0.4-0.5%</p>
<p>Cure rate GTD/GTN</p>
<p>98-100%</p>
<p>Incidence GTD</p>
<p>1:714 live births</p>
<p>PCOS in reproductive age</p>
<p>10-18%</p>
<p>Metabolic syndrome in PCOS</p>
<p>33%</p>
<p>Sickle cell heterozygous (trait) in UK</p>
<p>240,000</p>
<p>Sickle cell disease UK</p>
<p>12,500</p>
<p>Lifetime prevalence of uterovaginal prolapse</p>
<p>30-50%</p>
<p>Per cent of women who have had surgery for UV prolapse by 80yo</p>
<p>12%</p>
<p>VBAC success overall</p>
<p>72-75%</p>
<p>VBAC + prev vaginal delivery success</p>
<p>85-90%</p>
<p>Success of VBAC + prev CS for fetal malpresentation </p>
<p>84%</p>
<p>Success of VBAC if prev CS fetal distress</p>
<p>73%</p>
<p>Success of VBAC + prev cs for Labour dystocia</p>
<p>64%</p>
<p>Background risk VTE women in 1 yr</p>
<p>2:10,000</p>
<p>Risk VTE in CHC + ethinlyestradiol + levogernestrel/norgestimate/norethisterone</p>
<p>5-7:10,000</p>
<p>Risk of VTE in etonogestrel (ring) or norelgestromin (patch)</p>
<p>6-12: 10,000</p>
<p>Risk VTE with ethinylestradiol + gestodone/desogestrel/drosperinone</p>
<p>9-12:10,000</p>
<p>Conception rate after UPA (within 120hrs)</p>
<p>1.3%</p>
<p>Conception rate after LNG</p>
<p>2.2%</p>
<p>Women who have gonorrhiea and chlamydia co-infection </p>
<p>40%</p>
<p>UV prolapse lifetime prevalence</p>
<p>30-50%</p>
<p>Vaginal vault prolapse recurrence after uterosacral ligament suspension</p>
<p>5-12%</p>
<p>Recurrence rate of vaginal vault prolapse after sacrocolpopexy</p>
<p>3-5%</p>
<p>Rate of increased UI after VH</p>
<p>60% over 60yo</p>
<p>Dyspareunia after anterior repair</p>
<p>15%</p>
<p>Risks of sacrocolpopexy
- mesh erosion
- SBO
- ileus
- recurrence</p>
<p>10.5%
1.2%
0.3%
3-5%</p>
<p>Per cent of women in lifetime who will have surgery for ovarian mass</p>
<p>10%</p>
<p>Incidence of ovarian cyst in premenopausal being malignant</p>
<p>1:1000</p>
<p>Incidence of ovarian cyst being malignant in 50yo</p>
<p>3:1000</p>
<p>Per cent of TOA being malignant in postmenopausal</p>
<p>49%</p>
<p>Per cent with chronic pelvic pain after 1 episode 2 episodes 3 episodes Of PID/TOA</p>
<p>12%
30%
67%</p>
<p>Per cent of women under 40 affected by POI</p>
<p>1%</p>
<p>Most common cause of premature ovarian insufficiency</p>
<p>Idiopathic 90%
| Chromosomal, AI, infective and iatrogenic 10%</p>
<p>IVF - mild OHSS</p>
<p>33%</p>
<p>IVF - mod/severe OHSS</p>
<p>3-8%</p>
<p>Prevalence of POI</p>
<p>1:100</p>
<p>Main cause of POI</p>
<p>90% idiopathic</p>
<p>Sensitivity of amniocentesis for diagnosing fetal CMV?</p>
<p>60-70%</p>
<p>Percentage of clinically significant red cell autoantibodies in pregnancy</p>
<p>0.4%</p>
<p>Percentage of red cell autoantibodies in pregnancy</p>
<p>1.2%</p>
<p>Level of anti K to refer to fetal med</p>
<p>any</p>
<p>Level of anti D to refer to fetal med</p>
<p>>4</p>
<p>Level of anti C to refer to fetal med</p>
<p>>7.5</p>
<p>Level of anti E to refer to fetal med</p>
<p>When anti C detected</p>
<p>Aim of transfusion PCV for fetal anaemia</p>
<p>PCV 0.7-0.85</p>
<p>Aim of transfusion PCV for neonatal anaemia </p>
<p>PCV 0.5-0.6</p>
<p>Percentage of women with bipolar disorder, without family history, of developing postpartum pyschosis</p>
<p>1:4</p>
<p>Percentage of women with bipolar disorder, with family history, of developing postpartum pyschosis</p>
<p>1:2</p>
<p>Risk of congenital infection with recurrent CMV</p>
<p>1-2%</p>
<p>Risk of congenital infection with primary CMV</p>
<p>30-40%</p>
<p>What percentage of infants with congenital CMV infection are symptomatic?</p>
<p>10-15%</p>
<p>Maternal mortality in UK?</p>
<p>8.76 per 100,000</p>
<p>Percentage of twins in live births?</p>
<p>3%</p>
<p>Incidence of puerperal genital haematoma?
| Requiring surgical intervention?</p>
<p>1:700
| 1:1000</p>
<p>Congenital malformations of women with epilepsy without AEDs</p>
<p>2.8%</p>
<p>Valproate and congenital malformations</p>
<p>10.7%</p>
<p>AED Polytherapy and congenital malformations</p>
<p>16%</p>
<p>Risk of congenital malformations if previously affected child </p>
<p>16.8%</p>
<p>Lamotrigine and congenital malformations</p>
<p>2%</p>
<p>Carbamazepine and congenital malformations</p>
<p>3.4%</p>
<p>Keppra and congenital malformations</p>
<p>0.7%</p>
<p>Phenobarbital and congenital malformations</p>
<p>4.9%</p>
<p>Phenytoin and congenital malformations</p>
<p>7.36%</p>
<p>Risk of seizure in labour with epilepsy</p>
<p>1-4%</p>
<p>Percentage of brachial plexus injury in shoulder dystocia</p>
<p>2.3-16%</p>
<p>Maximum dose of lidocaine + adrenaline</p>
<p>7ml/kg</p>
<p>Risk of future PIH if previous PIH</p>
<p>16-47%</p>
<p>Risk of PET if previous PIH</p>
<p>2-7%</p>
<p>Risk of PIH if previous PET</p>
<p>13-53%</p>
<p>Risk of PET if previous PET</p>
<p>16%</p>
<p>Risk of PET if previous severe PET/HELLP/eclampsia led to birth <34/40</p>
<p>25%</p>
<p>Risk of PET if previous eclampsia led to birth <28/40</p>
<p>55%</p>
<p>Risk RDS at 37/40 ELCS</p>
<p>11%</p>
<p>Risk RDS at 38/40 ELCS</p>
<p>8%</p>
<p>Risk RDS at 39/40 ELCS</p>
<p>1.5%</p>
<p>Steroids reduce RDS by what per cent?</p>
<p>44%</p>
<p>Risk of miscarriage with amniocentesis</p>
<p>0.11%</p>
<p>Risk of miscarriage with CVS</p>
<p>0.22%</p>
<p>Percentage of inconclusive cffDNA tests</p>
<p>1.9-6%</p>
<p>cffDNA sensitivity and specificity for T21</p>
<p>99.4%, 99.9%</p>